$ cat ./records/gavi-approves-immunization-grants-to-36-of-the-worlds-poorest-cou-2001.txt
GAVI approves immunization grants to 36 of the world's poorest countries — backed by Gates Foundation
[RECORD.TXT] · cat --full
GAVI, the Vaccine Alliance — established with $750 million in Gates Foundation seed funding — approved its first round of grants to 36 of the world's poorest countries, representing over $600 million in five-year immunization commitments. The grants covered new and underused vaccines including Hepatitis B, Hib, and yellow fever. The rollout marked the largest coordinated international expansion of child immunization coverage in history and directly demonstrated the impact of Gates's founding investment in the alliance.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
First GAVI-funded vaccines delivered to Africa — enabled by Gates Foundation supply chain investment
Next →
DOJ and Microsoft reach antitrust consent decree — ending the landmark case without a breakup
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.